LEADER 02820nam 2200697 450 001 9910795918203321 005 20230807213446.0 010 $a1-137-38138-8 024 7 $a10.1057/9781137381385 035 $a(CKB)3720000000051321 035 $a(EBL)4001669 035 $a(SSID)ssj0001533958 035 $a(PQKBManifestationID)12638305 035 $a(PQKBTitleCode)TC0001533958 035 $a(PQKBWorkID)11486214 035 $a(PQKB)10805165 035 $a(MiAaPQ)EBC4001669 035 $a(DE-He213)978-1-137-38138-5 035 $a(MiAaPQ)EBC6353625 035 $a(Au-PeEL)EBL6353625 035 $a(OCoLC)912422502 035 $a(EXLCZ)993720000000051321 100 $a20210928d2015 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aRace, caste, and indigeneity in Medieval Spanish travel literature /$fMichael Harney 205 $a1st ed. 2015. 210 1$aNew York, New York State :$cPalgrave Macmillan,$d[2015] 210 4$dŠ2015 215 $a1 online resource (256 p.) 225 1 $aThe New Middle Ages 300 $aDescription based upon print version of record. 311 $a1-349-67773-6 311 $a1-137-38137-X 320 $aIncludes bibliographical references (pages [207]-221) and index. 327 $aMachine generated contents note: -- Introduction 1. Concepts of Race, Caste, and Indigeneity in Medieval Iberia 2. Race 3. Caste 4. IndigeneityConclusion: The Tourist in the Text. 330 $aThe origins of present-day Ibero-American racialization can be traced to the period when Europe straddled the boundary between the Middle Ages and the era of New World exploration. Focusing on themes of race, caste, and indigeneity in travel narratives, Harney explores this already internationalized world of late-medieval and early-modern Europe. 410 0$aThe New Middle Ages 606 $aSpanish American prose literature$yTo 1800$xHistory and criticism 606 $aTravelers' writings, Spanish$xHistory and criticism 606 $aRace in literature 606 $aIndigenous peoples in literature 606 $aCaste in literature 615 0$aSpanish American prose literature$xHistory and criticism. 615 0$aTravelers' writings, Spanish$xHistory and criticism. 615 0$aRace in literature. 615 0$aIndigenous peoples in literature. 615 0$aCaste in literature. 676 $a860.9/32 686 $aHIS045000$aLIT000000$aLIT004280$aLIT011000$2bisacsh 700 $aHarney$b Michael$f1948-$0175239 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910795918203321 996 $aRace, caste, and indigeneity in Medieval Spanish travel literature$93793459 997 $aUNINA LEADER 06019nam 22006735 450 001 9910552988503321 005 20251219095257.0 010 $a9781071620106 010 $a107162010X 024 7 $a10.1007/978-1-0716-2010-6 035 $a(CKB)5580000000286333 035 $a(DE-He213)978-1-0716-2010-6 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/79383 035 $a(PPN)260826472 035 $a(oapen)doab79383 035 $a(DNLM)9918486468206676 035 $a(EXLCZ)995580000000286333 100 $a20220225d2022 u| 0 101 0 $aeng 135 $aurnn#008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAntisense RNA Design, Delivery, and Analysis /$fedited by Virginia Arechavala-Gomeza, Alejandro Garanto 205 $a1st ed. 2022. 210 $aNew York$cSpringer Nature$d2022 210 1$aNew York, NY :$cSpringer US :$cImprint: Humana,$d2022. 215 $a1 online resource (XVII, 422 p. 69 illus., 59 illus. in color.) 225 1 $aMethods in Molecular Biology,$x1940-6029 ;$v2434 311 08$a9781071620090 311 08$a1071620096 327 $aIntroduction and History of the Chemistry of Nucleic Acids Therapeutics -- Antisense RNA Therapeutics: A Brief Overview -- Design of Bifunctional Antisense Oligonucleotides for Exon Inclusion -- Design and Delivery of SINEUP: A New Modular Tool to Increase Protein Translation -- How to Design U1 snRNA Molecules for Splicing Rescue -- Conjugation of Nucleic Acids and Drugs to Gold Nanoparticles -- Determination of Optimum Ratio of Cationic Polymers and Small Interfering RNA with Agarose Gel Retardation Assay -- Generation of Protein-Phosphorodiamidate Morpholino Oligomer Conjugates for Efficient Cellular Delivery via Anthrax Protective Antigen -- Development and Use of Cellular Systems to Assess and Correct Splicing Defects -- Modeling Splicing Variants Amenable to Antisense Therapy by Use of CRISPR-Cas9-Based Gene Editing in HepG2 Cells -- In Vitro Models for the Evaluation of Antisense Oligonucleotides in Skin -- In Vitro Delivery of PMOs in Myoblasts by Electroporation -- Rapid Determination of MBNL1 Protein Levels by Quantitative Dot Blot for Evaluation of Antisense Oligonucleotides in Myotonic Dystrophy Myoblasts -- Evaluation of Exon Skipping and Dystrophin Restoration in In Vitro Models of Duchenne Muscular Dystrophy -- Generation of Human iPSC-Derived Myotubes to Investigate RNA-Based Therapies In Vitro -- Eye on a Dish Models to Evaluate Splicing Modulation -- Establishment of In Vitro Brain Models for AON Delivery -- Considerations for Generating Humanized Mouse Models to Test Efficacy of Antisense Oligonucleotides -- Generation of Humanized Zebrafish Models for the In Vivo Assessment of Antisense Oligonucleotide-Based Splice Modulation Therapies -- Use of Small Animal Models for Duchenne and Parameters to Assess Efficiency upon Antisense Treatment -- In Vivo Models for the Evaluation of Antisense Oligonucleotides in Skin -- Delivery of Antisense Oligonucleotides to the Mouse Retina -- Delivery of Antisense Oligonucleotides to the Mouse Brain by Intracerebroventricular Injections -- Intrathecal Delivery of Therapeutic Oligonucleotides for Potent Modulation of Gene Expression in the Central Nervous System -- Preclinical Safety Assessment of Therapeutic Oligonucleotides -- Preclinical Evaluation of the Renal Toxicity of Oligonucleotide Therapeutics in Mice -- Protocol for Isolation and Culture of Mouse Hepatocytes (HCs), Kupffer Cells (KCs), and Liver Sinusoidal Endothelial Cells (LSECs) in Analyses of Hepatic Drug Distribution -- Patent Considerations When Embarking on New Antisense Drug Programs. 330 $aThis open access volume gathers a variety of models, delivery systems, and approaches that can be used to assess RNA technology for exploiting antisense as a therapeutic intervention. Beginning with a section on the design of antisense technology and their delivery, the book continues by covering model systems developed to evaluate efficacy, both in vivo and in vitro, as well as methods to evaluate preclinically the toxicity associated with these new potential drugs, and intellectual property considerations. Written for the highly successful Methods in Molecular Biology series, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Antisense RNA Design, Delivery, and Analysis provides basic knowledge and a large collection of methods to facilitate the workof newcomers to this vibrant and expanding field. This book was conceived thanks to the network DARTER (Delivery of Antisense RNA Therapeutics). DARTER is funded by the EU Cooperation of Science and Technology (COST), which aims to enhance interaction and collaborations between researchers in Europe and other countries. 410 0$aMethods in Molecular Biology,$x1940-6029 ;$v2434 606 $aTherapeutics 606 $aBiomaterials 606 $aNucleic acids 606 $aTherapeutics 606 $aNucleic Acid 606 $aĀcids nucleics$2thub 606 $aRNA$2thub 606 $aTerāpia genčtica$2thub 608 $aLlibres electrōnics$2thub 615 0$aTherapeutics. 615 0$aBiomaterials. 615 0$aNucleic acids. 615 14$aTherapeutics. 615 24$aNucleic Acid. 615 7$aĀcids nucleics. 615 7$aRNA 615 7$aTerāpia genčtica 676 $a615.5 700 $aArechavala-Gomeza$b Virginia$4edt$01300027 702 $aArechavala-Gomeza$b Virginia$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aGaranto$b Alejandro$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910552988503321 996 $aAntisense RNA Design, Delivery, and Analysis$93025345 997 $aUNINA